News | April 08, 2022
Cadila Pharma launches world’s first three-dose rabies vaccine
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
More than 120 speakers and 5,000 delegates are expected to attend
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Recommendation is based on pivotal data from the phase III POLARIX study
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
With the implementation of this project, a total of 1,030 acres of cultivable land can be irrigated per crop cycle
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Subscribe To Our Newsletter & Stay Updated
